Xoma | XOMA - Debt


Xoma reported $120.79M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Agenus USD 35.54M 2.34M Mar/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Ardelyx USD 207.61M 968K Sep/2025
aTyr Pharma USD 1.84M 8K Sep/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Celldex Therapeutics USD 2.62M 410K Sep/2025
Curis USD 0 0 Jun/2022
Eli Lilly USD 42.51B 2.6B Sep/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Incyte USD 40.41M 855K Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Prothena USD 9.08M 699K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Xoma USD 120.79M 3.27M Jun/2024